CAMP4 Therapeutics (NASDAQ:CAMP) Raised to “Hold” at Zacks Research

CAMP4 Therapeutics (NASDAQ:CAMP) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Several other brokerages have also weighed in on CAMP. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a report on Friday. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Piper Sandler reiterated an “overweight” rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Finally, Weiss Ratings raised CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, CAMP4 Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $9.56.

CAMP4 Therapeutics Stock Down 2.0%

Shares of NASDAQ:CAMP opened at $4.90 on Monday. CAMP4 Therapeutics has a 52-week low of $1.41 and a 52-week high of $7.75. The company has a 50 day moving average of $4.10 and a two-hundred day moving average of $4.32. The company has a market capitalization of $307.48 million, a price-to-earnings ratio of -2.11 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The firm had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. On average, equities analysts anticipate that CAMP4 Therapeutics will post -0.66 earnings per share for the current year.

Insider Activity

In other CAMP4 Therapeutics news, Director Richard A. Young acquired 16,378 shares of CAMP4 Therapeutics stock in a transaction dated Monday, August 3rd. The stock was acquired at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the transaction, the director owned 186,388 shares in the company, valued at approximately $307,540.20. This represents a 9.63% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders purchased 36,031 shares of company stock worth $59,451 in the last three months. Insiders own 21.69% of the company’s stock.

Institutional Trading of CAMP4 Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth about $61,000. Jefferies Financial Group Inc. bought a new position in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $70,000. State Street Corp boosted its holdings in shares of CAMP4 Therapeutics by 52.7% in the fourth quarter. State Street Corp now owns 39,700 shares of the Wireless communications provider’s stock valued at $243,000 after acquiring an additional 13,700 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of CAMP4 Therapeutics during the fourth quarter valued at approximately $86,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in CAMP4 Therapeutics during the fourth quarter worth approximately $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.